drugset / Trial / NCT04517357
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, 2-arm Phase 2 study to evaluate the efficacy and safety of Fluzoparib with Apatinib versus Fluzoparib alone, as treatment, in relapsed ovarian cancer patients. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 2 portion of the study.
Timeline
- Start
- 2020-10-16
- Primary completion
- 2023-11-30
- Completion
- 2024-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluzoparib | Small molecule | — | — |
| Subject | Rivoceranib | Small molecule | — | — |
Indications
No indication recorded.